Please assess the completion status of the following clinical trial:

Trial Title: Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. A known history of Type 2 Diabetes receiving either diet alone or oral antidiabetic drugs (OAD) including insulin secretagogues, pioglitazone, DPP4 inhibitors, or metformin as monotherapy or in combination therapy, or low-dose insulin at \<0.5 unit/kg/day.~2. Males or females between the ages of 18 and 80 years discharged after hospital admission from general medicine and surgery services (non-Intensive Care Unit setting).~3. Subjects with an admission / randomization BG \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~4. Admission HbA1c between 7% and 10%~5. BMI range: \> 25 Kg/m\^2 and \< 45 Kg/m\^2~Exclusion Criteria:~1. Age \< 18 or \> 80 years~2. Subjects with increased blood glucose (BG) concentration, but without a history of diabetes (stress hyperglycemia)~3. Subjects with a history of type 1 diabetes (suggested by BMI \< 25 Kg/m\^2 requiring insulin therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria).~4. Treatment with high-dose (\>0.5 unit/kg/day) insulin or with GLP-1 RA during the past 3 months prior to admission.~5. Patients that required ICU care during the hospital admission.~6. Recurrent severe hypoglycemia or hypoglycemic unawareness.~7. Subjects with gastrointestinal obstruction, gastroparesis, history of pancreatitis or those expected to require gastrointestinal suction.~8. Patients with clinically relevant pancreatic or gallbladder disease.~9. Patients with unstable or rapidly progressing renal disease or severe renal impairment (creatinine clearance \< 30 ml/min)~10. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease),~11. History of hypersensitivity to exenatide~12. Treatment with oral or injectable corticosteroid (equal to a prednisone dose \>5 mg/day), parenteral nutrition and immunosuppressive treatment.~13. Patients with history of heavy alcohol use (female \> 2 drinks per day, male \> 3 drinks per day) or drug abuse within 3 months prior to admission.~14. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~15. Female subjects who are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide inpatient (Type: ACTIVE_COMPARATOR): Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
- Exenatide plus glargine insulin inpatient (Type: ACTIVE_COMPARATOR): Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
- Basal bolus regimen inpatient (Type: ACTIVE_COMPARATOR): Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
- Exenatide outpatient (Type: ACTIVE_COMPARATOR): Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels \> 140 mg/dL per the sliding scale.
- Insulin Only (Type: ACTIVE_COMPARATOR): Patients with Type 2 Diabetes will be treated with Insulin only

Based on this trial design, predict the completion outcome and termination type (if applicable).